The 2024 ASTRO Annual Meeting, held from September 28 to October 2 at the Walter E. Washington Convention Center in Washington, DC, brought together thousands of radiation oncology professionals. The conference, themed “Targeting Provider Wellness for Exceptional Patient Care,” gave attendees the opportunity to engage with leading experts and explore cutting-edge developments in radiation therapy, patient safety, and strategies to enhance provider wellness. 

One of the major topics that received significant attention was breast cancer, a critical issue given that over 300,000 new cases are diagnosed annually in the U.S. Experts presented the latest clinical trials, emerging research, and innovative treatment approaches that promise to reshape the landscape of breast cancer care. 

Now, let’s explore the highlights of the cutting-edge research presented, offering insights into the advancements shaping the future of breast cancer.

Validation of Spanish-Language Surveys Utilized for the Navigator-Assisted Hypofractionation Program to Aid Hispanic-American Breast Cancer Patients

  • Key Takeaway: Cancer is the leading cause of death among Hispanic and Latinx patients in the U.S., accounting for 22% of all mortality. Disparities in access to radiation therapy and treatment outcomes among Hispanic-American breast cancer patients emphasize the need for targeted interventions. The NAVAH program addresses these disparities through a culturally sensitive, Spanish-language survey designed to identify barriers. Initial results from a pilot study with six volunteers show the survey is feasible and reveals concerns about racial and ethnic prejudice, as well as income-based treatment differences. Further investigation in breast cancer patients undergoing radiation therapy is ongoing.
  • Link to Summary

Tailoring Treatment Margins: A Study of PTV Reduction Using X-Ray Based Adaptive Radiotherapy for Stereotactic Partial Breast Irradiation (A-SPBI) Treatments

  • Key Takeaway: This study evaluated the adequacy of a 3 mm CTV to PTV margin expansion for patients undergoing adaptive radiotherapy stereotactic partial breast irradiation (A-SPBI), aiming to reduce the conventional 1.0 cm margin. Fiducial marker motion was measured, showing mean movements of 2.18 mm laterally, 1.86 mm anterior/posteriorly, and 1.94 mm superior/inferiorly. Statistical analysis confirmed that the 3 mm margin is sufficient, with movements significantly less than 3 mm and 2.5 mm thresholds, but not significantly different from the 2 mm threshold. The 3 mm margin was deemed clinically appropriate for daily adaptive SBPI treatments.
  • Link to Summary

Early Results of a Phase II Trial of Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients (UNIQUE)

  • Key Takeaway:  This phase II study evaluated the feasibility of ultra-hypofractionated whole breast radiation therapy (u-WBRT) with or without simultaneous tumor bed boost (SIB) in early-stage breast cancer (ESBC). Among 151 patients, only 10.8% experienced pre-defined toxicities, and none showed signs of relapse. Most patients had excellent cosmetic outcomes, and acute toxicity rates, including breast edema and lymphocytopenia (LP), were low. Longer follow-up and larger trials are needed to confirm the long-term safety and effectiveness of this treatment approach.
  • Link to Summary

Accelerated Partial Breast Irradiation for Low-Risk Hormone-Sensitive Breast Cancer is Underutilized but Increasing in the National Cancer Database 2010-2021

  • Key Takeaway: This study analyzed data from the National Cancer Database (NCDB) to examine the use of accelerated and hypofractionated partial breast irradiation (A/PBI) in early-stage breast cancer. Among 317,437 eligible patients, 10.7% received A/PBI, while 89.3% underwent whole breast irradiation (WBI). A/PBI use increased significantly from 8% (2010-2017) to 13.7% (2018-2021). However, even in the most recent year, less than 20% of eligible patients received A/PBI, with only 10.6% treated using the more convenient and less toxic 30Gy/5Fx regimen or brachytherapy. Despite growing use, A/PBI remains underutilized.
  • Link to Summary

Accelerated Partial Breast Irradiation for Patients with Invasive Lobular Carcinoma

  • Key Takeaway: This study evaluated outcomes for invasive lobular carcinoma (ILC) patients treated with accelerated partial breast irradiation (APBI) following breast-conserving surgery. Among 132 patients with ILC or mixed histology, only two local recurrences were observed over 530 person-years, resulting in a 4-year recurrence rate of 3%. No regional or distant recurrences occurred, and overall survival was 98% at 48 months. Although larger trials with longer follow-up are needed to confirm APBI’s safety for ILC, these promising results align with outcomes seen in invasive ductal carcinoma trials.
  • Link to Summary

Breast Cancer-Related Lymphedema Quantified by Bioimpedance Spectroscopy in Patients Undergoing Axillary Node Dissection, Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) and Regional Nodal Irradiation

  • Key Takeaway: This study assessed breast cancer-related lymphedema (BCRL) in patients undergoing axillary node dissection (ALND), comprehensive nodal irradiation (RNI), and LYMPHA surgery. Among 54 patients, 16.7% developed subclinical lymphedema (SLE) or lymphedema (LE) at one-year follow-up. Significant predictors of BCRL included age, ethnicity, and chest wall/breast boost. The study showed that adding LYMPHA reduced the incidence of BCRL to 16.7%, compared to historical rates of 20-40%. Larger studies are needed to confirm these findings and further evaluate risk factors.
  • Link to Summary

Relationship of Immediate Breast Reconstruction and the Development of Lymphedema in Breast Cancer Patients with Radiotherapy

  • Key Takeaway: This study investigated the impact of immediate breast reconstruction on the incidence of upper extremity lymphedema in breast cancer patients who underwent mastectomy and radiotherapy. After a median follow-up of 49 months, 121 patients developed lymphedema, with axillary lymph node dissection (ALND) significantly associated with higher incidence rates (16.6% vs. 4.9%). Conversely, immediate breast reconstruction was linked to a lower incidence of lymphedema (8.5% vs. 18.1%). These associations remained significant in multivariate analyses. The study highlights lymph node dissection as a critical factor in lymphedema development and suggests that immediate reconstruction may reduce its incidence, warranting further validation in future research.
  • Link to Summary

Predicting Chemoradiotherapy Induced Cardiotoxicity in Breast Cancer Patients Using Machine Learning Based Clinical, Imaging and Dosimetric Radiomics Features

  • Key Takeaway: This study addresses the need for effective risk stratification strategies to predict cardiotoxicity in breast cancer patients, who are at risk of heart damage from treatment. The research found that 58% of participants exhibited cardiotoxicity six months post-treatment, with significant reductions in left ventricular ejection fraction and global longitudinal strain (p < 0.001). Utilizing support vector machine (SVM) modeling, the study demonstrated that incorporating various data types—dose-volume histogram (DVH), demographic, clinical, and radiomics features—led to improved prediction performance, achieving area under the curve (AUC) scores of 70%, 75%, 85%, and 95%, respectively. These findings suggest that combining patient data and advanced machine learning techniques can enhance the prediction of cardiac toxicity following chemo-radiotherapy in breast cancer patients.
  • Link to Summary

Beyond Traditional Borders: Outcomes with Curative Intent Therapy for Stage IV Breast Cancer Defined by Non-Regional Nodal Metastases

  • Key Takeaway: This study investigates the outcomes of breast cancer patients with isolated non-regional lymph node metastases, a rare and poorly understood condition. Eleven female patients (median age 53 years) were followed for a median of 1.6 years. Most had de novo breast cancer (82%), primarily hormone receptor-positive and HER2-negative subtypes. The non-regional lymph nodes involved included contralateral internal mammary, axillary, mediastinal, and ipsilateral cervical nodes. Treatment included neoadjuvant chemotherapy for ten patients, with 73% undergoing mastectomy and 64% having axillary lymph node dissection. Radiation therapy (RT) was delivered to a total dose of 60-70 Gy in 30-35 fractions, targeting non-regional lymph nodes in 72% of cases. The study found a two-year overall survival rate of 74% and a distant disease-free survival rate of 68%. However, one-third of patients experienced rapid disease progression, while others achieved over five years without evidence of disease. The acute grade 3 toxicity was low, with dermatitis occurring in one patient, and late grade 2 toxicity, primarily breast or chest wall fibrosis, occurred in five patients. The results suggest that comprehensive systemic and locoregional therapy may be effective for patients with Stage IV breast cancer confined to non-regional lymphatics, with low treatment-related toxicity. Curative intent therapy is recommended for these patients.
  • Link to Summary

In conclusion, the insights presented at the conference reflect a significant advancement in our understanding of breast cancer treatment and its complexities. In addition, the collective knowledge shared not only paves the way for future research but also inspires hope for improved survival and quality of life for patients worldwide. 

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2024 Guideline Central, All rights reserved.